title: [Evaluation of safety of prophylactic use of immunoglobulins against viral hemorrhagic fevers from horse blood sera].
abstract: OBJECTIVE
  Evaluate safety of prophylaxis of viral hemorrhagic fevers by specific heterologous immunoglobulins.
  
  
  METHODS
  Clinical-laboratory examination of 24 individuals after intramuscular administration of heterologous Ebola immunoglobulin was carried out. Anaphylactogenicity of the immunoglobulins was studied by WD 42-28-8-89 in guinea pigs compared with commercial preparations.
  
  
  RESULTS
  Immediate type reactions were not observed. In individuals with normal anamnesis the number of local reactions was 31%, general in the form of lung serum disease - 13%. In individuals with unfavorable anamnesis against the background of desensitization therapy there were almost no reactions; without it local reactions were present in 50%, mild severity serum lung disease - in 17%, medium - in 33%. Immunoglobulins against especially dangerous viral agents by anaphylactogenic properties did not differ from commercial heterologous preparations.
  
  
  CONCLUSIONS
  Application of specific immunoglobulins from horse blood sera (the main means of protection from dangerous and especially dangerous exotic viral infections) with compliance by desensitization principles is relatively safe. Safe level of sensitization properties is characterized by anaphylaxis index up to 3.7 for guinea pigs.
authors.forename: A L
authors.initials: AL
authors.lastname: Khmelev
authors.forename: I V
authors.initials: IV
authors.lastname: Borisevich
authors.forename: N K
authors.initials: NK
authors.lastname: Chernikova
authors.forename: A A
authors.initials: AA
authors.lastname: Makhlaĭ
authors.forename: V V
authors.initials: VV
authors.lastname: Mikhaĭlov
authors.forename: A K
authors.initials: AK
authors.lastname: Iakovlev
authors.forename: V N
authors.initials: VN
authors.lastname: Podkuĭko
authors.forename: V P
authors.initials: VP
authors.lastname: Krasnianskiĭ
authors.forename: S V
authors.initials: SV
authors.lastname: Borisevich
authors.forename: V P
authors.initials: VP
authors.lastname: Bondarev
mesh_terms: D000328:Adult; D000707:Anaphylaxis; D000818:Animals; D000914:Antibodies, Viral / Q000008:administration & dosage* / Q000097:blood; D046129:Ebola Vaccines / Q000008:administration & dosage* / Q000097:blood; D029043:Ebolavirus / Q000276:immunology; D005260:Female; D006168:Guinea Pigs; D019142:Hemorrhagic Fever, Ebola / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D006736:Horses; D006801:Humans; D007114:Immunization; D007136:Immunoglobulins / Q000008:administration & dosage* / Q000097:blood; D007273:Injections, Intramuscular; D008168:Lung; D008297:Male
chemical_list: D000914:Antibodies, Viral; D046129:Ebola Vaccines; D007136:Immunoglobulins